Evidence map›Paper›PMID 36188590›Full record

ArticleFrontiers in pharmacology2022

Curcumin and berberine co-loaded liposomes for anti-hepatocellular carcinoma therapy by blocking the cross-talk between hepatic stellate cells and tumor cells.

Jingliang Wu, Cuiping Qi, Hao Wang, Qing Wang, Jingui Sun, Jinping Dong, Guohua Yu, Zhiqin Gao, Bo Zhang, Guixiang Tian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Cell death pathways in response toInfection and immunity · 2025
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jingliang WuSchool of Nursing, Weifang University of Science and Technology, Weifang, China.
Cuiping QiSchool of Nursing, Weifang University of Science and Technology, Weifang, China.
Hao WangDepartment of Oncology, Weifang People's Hospital, Weifang, China.
Qing WangSchool of Bioscience and Technology, Weifang Medical University, Weifang, China.
Jingui SunSchool of Nursing, Weifang University of Science and Technology, Weifang, China.
Jinping DongSchool of Nursing, Weifang University of Science and Technology, Weifang, China.
Guohua YuDepartment of Oncology, Weifang People's Hospital, Weifang, China.
Zhiqin GaoSchool of Bioscience and Technology, Weifang Medical University, Weifang, China.
Bo ZhangSchool of Pharmacy, Weifang Medical University, Weifang, China.
Guixiang TianSchool of Bioscience and Technology, Weifang Medical University, Weifang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer-associated fibroblasts (CAFs) are a major component of the tumor microenvironment (TME). In hepatocellular carcinoma (HCC), quiescent hepatic stellate cells (HSCs) could be activated to become CAFs, which play a critical role in tumor progression and drug resistance. Therefore, recent efforts have been focused on combining anti-HSC and pro-apoptotic activities to improve anti-tumor efficacy of drugs. In this study, glycyrrhetinic acid and hyaluronic acid-modified liposomes (GA-HA-Lip) were prepared for co-delivery of curcumin (CUR) and berberine (BBR) for the treatment of HCC. Furthermore, we established the LX-2+BEL-7402 co-cultured cell model and implanted the m-HSCs+H22 cells into a mouse to evaluate the anti-tumor effect of CUR&BBR/GA-HA-Lip both

Indexed as

berberinecombination therapycurcumindeliveryliposomes

Identifiers

PMID36188590
PMCPMC9515508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.